Recently, Acchrom-Tech announced that it has completed angel round financing, led by Boyuan Capital, and jointly invested by Chende Capital and Guotou Chuanghe. The funds obtained from this round of financing will mainly be used to further enhance the company's ability to provide customers with complete chromatographic solutions, as well as to expand sales channels. Changhai Capital serves as the exclusive financial advisor for this round of financing.

Chromatography is the largest single product market in the field of life science analysis, widely used in pharmaceutical, chemical, environmental, and clinical testing fields, mainly playing the role of metrology. Currently, China's stock market has exceeded 10 billion yuan per year and continues to grow. However, currently, liquid chromatography in the Chinese market is mainly monopolized by several major foreign manufacturers, with domestic brands accounting for less than 5%. The reason for this phenomenon is, on the one hand, due to the gap between domestic manufacturers and imported brands in terms of hardware strength such as instrument and consumable performance; On the other hand, domestic manufacturers also lack professional application service teams to provide customers with direct solutions for specific landing application scenarios; Customers often need temporary intervention from manufacturers during use, which further deepens their distrust of domestic brands.

Established in 2015, Acchrom-Tech is one of the few high-end chromatography brands in China that can break the monopoly of foreign brands and achieve a complete closed-loop of chromatography equipment, consumables, software, and services. The founder and chairman of the company, Wang Lichun, has over 10 years of sales and management experience in the chromatography and mass spectrometry industry, and has a deep understanding of chromatography underlying technology and industry pain points. In terms of technology, the company has united a strong research and development team from Dalian Institute of Chemical Physics in China, as well as senior R&D workers and engineers from several well-known scientific instrument enterprises, to create a complete product system; The sales team is led by Mr. Yu Xiaoran, former General Manager of Waters China, and other senior experts in the industry, with rich customer channels. At the same time, based on the characteristics of Chinese customers, more practical application services are launched.

Instrument: It has covered major B-end users and has a good brand reputation

At present, Acchrom-Tech has established a rich product matrix of HPLC (High Performance Liquid Chromatography) and UHPLC (Ultra High Performance Liquid Chromatography), with a complete range of detectors to meet the different detection needs of customers. The number of self owned branded instruments in the mainstream chromatographic application market has reached a scale of one thousand units, widely covering major pharmaceutical companies, food enterprises, research institutes, and government agencies. The accuracy, stability, and injection accuracy of the product are all in line with international standards and have been deeply recognized by customers.

The company adopts a diversified sales strategy and collaborates with multiple national and provincial regulatory agencies to develop and update national standards, thereby promoting "Chinese product solutions". At present, the instruments of Acchrom-Tech have been deployed to national and multiple provincial-level drug testing institutes and disease control centers, receiving widespread attention from expert leaders. In February of this year, the company also reached a strategic cooperation with the international mass spectrometry brand SCIEX to jointly create domestically produced liquid chromatography-mass spectrometer products, helping the company form a more complete product ecosystem for chromatography.

Hardware, consumables, software, and service system: truly meeting the practical application needs of users

After years of development, Acchrom-Tech has established a complete chromatographic column (consumables), software, and application service system, forming a complete product ecosystem together with the instrument. The company has developed a series of chromatographic column products for different scenarios such as pharmaceuticals and life science analysis, which have excellent performance in separation, stability, and other aspects; Based on the network version architecture, compliance software has mastered the key to opening up core B-end markets such as pharmaceutical companies; We have accumulated a large number of SOP solutions in the fields of food, chemical medicine, traditional Chinese medicine, innovative medicine, and environment, and high-quality, low-cost application services have greatly enhanced user stickiness.

Regarding the future: Seizing the opportunity of domestic substitution policies and building a Chinese life science tool platform enterprise

In recent years, with the changes in the international situation, the country's emphasis on "bottleneck" technology has been increasing. The pace of domestic substitution has gradually shifted from clinical instruments and drugs to more advanced and sophisticated life science tools, and the chromatography industry has also deeply felt this change. As an industry veteran, Wang Lichun has a deep understanding. "In the past, China's chromatography products were not of good quality, and the standards were all set by foreign products. Even if you want to sell them, you don't have a chance. After 2019, a series of policies introduced by the government, including the implementation of new national standards, encouragement for bidding in various regions, and support from experts and teachers, have greatly increased the opportunities for localization in the entire market. We, as entrepreneurial partners, have worked in various international large factories before, and we feel it is our responsibility to seize this opportunity and contribute our own strength to China's realization of independent life science tools."

With this goal in mind, Acchrom-Tech is steadily expanding its layout in research and development, marketing, and sales. Next, in addition to its layout in the liquid chromatography and mass spectrometry industries, Acchrom-Tech will also continue to expand and innovate in high-end instruments and consumables such as ion chromatography and other laboratories, striving to become a platform enterprise for Chinese life science tools.

Image:Acchrom-Tech S6000 independently developed instrument+Chromloong independently developed chromatographic software entering a certain drug testing institute

Various perspectives:

Li Han, Vice President of Boyuan Capital, stated that scientific instruments are not only tools for understanding the unknown world, but also the foundation of technological innovation. The domestic scientific instrument industry started late and has a weak foundation. Various high-end scientific instruments, represented by chromatography and mass spectrometry, have long relied on imports. In recent years, both national and local governments, as well as end customers, have attached greater importance to and supported domestically produced scientific instrument products. Opportunities for the rise of this industry are brewing. Boyuan Capital has been focusing on the field of scientific instruments for a long time and has established multiple companies, including Hanchen Guangyi (fully automated high-throughput gene detection system), Finder Biotech (single cell sequencing system), Qicarbon Technology (nanopore sequencing system), and Uce Biotech (single molecule immune system). Chromatography and mass spectrometry are the largest categories of analytical instruments. The founding team of Acchrom-Tech has been rooted in this field for many years, accumulating multiple self-developed technologies, forming a complete closed loop of instruments, consumables, software, applications, and after-sales. We highly recognize the resilience and profound industry accumulation of the company's team, and believe that Acchrom-Tech can become a leading enterprise in domestic scientific instruments in the future.

Chende Capital stated that the field of life science instruments is one of Chende Capital's key areas of focus. The Acchrom-Tech team has successfully established liquid phase analysis applications in multiple industries in the past, and the company has accumulated sufficient experience in software, hardware, systems, and consumables through independent research and cooperation. In the process of interacting with Acchrom-Tech, we fully felt the profound understanding of the industry, enterprising entrepreneurial spirit, and solid work style of the founder Mr. Wang and the team. We hope that under the leadership of Mr. Wang and the professional team, Acchrom-Tech can continuously launch excellent products and services with a good reputation, and become a benchmark enterprise in the chromatographic analysis industry as soon as possible.

The biopharmaceutical team of Guotou Chuanghe stated that Acchrom-Tech has a deep understanding of liquid chromatography separation technology and has established a complete chromatography product ecosystem and professional service system. Guotou Chuanghe will support Acchrom-Tech to improve its leading life science instrument product layout, increase research and development investment, continue to strengthen its technical and service capabilities, and achieve its brand vision.

Wang Keshu, partner of Changhai Capital, stated that it is a great honor to assist Acchrom-Tech in completing the first round of financing, laying the foundation for the company's future high-speed development. With the increasing attention from the national level, the localization of high-end life science instruments is entering an ice breaking era. We believe that Acchrom-Tech's complete product ecosystem, comprehensive talent reserves, and strong market channel expansion capabilities will jointly promote it to become a leader in the industry, sparking a new wave of domestic substitution of core research and development production equipment in multiple fields such as pharmaceuticals, chemicals, and the environment.

About Boyuan Capital

Established in 2017, Boyuan Capital is a professional investment institution dedicated to investing in and incubating outstanding medical and health startups in the Chinese market. At present, Boyuan Capital manages two RMB funds and two USD funds, with a total fund management scale exceeding 7 billion yuan. Boyuan Capital is not only an investor, but also a long-term partner of entrepreneurs. Since its establishment, Boyuan Capital has always adhered to the principle of putting entrepreneurs at the center, providing long-term assistance and actively empowering outstanding entrepreneurs in the medical and health industry, building an industry ecosystem, and building a new generation of leading enterprises in China's medical and health industry.

About Chende Capital

Chende Capital is an investment institution focused on innovative medical technology and cutting-edge biotechnology sub sectors. It is managed and operated by a professional team with senior medical industry background, and manages multiple RMB and USD funds under its umbrella.

Chende Capital adheres to the investment philosophy of "focus, excellence, and reputation", based on its profound industrial resources in the medical field and years of in-depth research and cultivation, to gain insight into the latest international technological trends in a timely manner and seize investment opportunities brought about by technological innovation. Chende Capital is committed to discovering top companies with industry leadership potential, and through an interconnected and win-win investment methodology and a precise and pragmatic post investment empowerment system, we work together with entrepreneurs to build an industrial ecosystem, grow together, and create sustainable and excellent returns for investors.

Regarding Guotou Chuanghe

Guotou Chuanghe is a professional guidance fund and industry fund management institution of Guotou Group, with a direct management scale of over 40 billion yuan, focusing on equity investment, venture capital, and fund investment in strategic emerging industries. Under the advocacy of the National Development and Reform Commission, we have taken the lead in establishing the National Innovation Biomedical, Artificial Intelligence, New Materials, and Network Information Security Entrepreneurship Investment Service Alliance. As a member unit of the China Securities Investment Fund Industry Association, we continuously improve the investment ecosystem, gather the joint efforts of mass entrepreneurship and innovation, and promote the development of emerging industries.

About Changhai Capital

Changhai Capital is a financial advisor specializing in the medical and health field, providing enterprises with in-depth and customized financing strategies and services. The team has rich industry experience in the fields of life sciences, medical devices, IVD, and medical services. They have led and participated in the financing of multiple star enterprises, assisting them in rapid growth and maximizing their value.